Trial Purpose

The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.

There is no primary hypothesis to be tested for this study.

View full trial information on Clinicaltrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT05853367

When speaking to your doctor, please have the trial identifier number available.

About The Trial

Trial Phase Icon

Phase 1

Tests the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital.

Trial start Icon

Dates

  • Actual study start date July 6, 2023
  • Estimated primary completion date February 12, 2028
  • Estimated study completion date February 12, 2028

Eligibility

Conditions Icon

Conditions

Advanced Solid Tumors, Metastatic Solid Tumors

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

All

Trial locations